Situaties waarbij sedatie op de IC nodig is artificial sleep conditions Sedation need
Conditions
Interventions
None listed
Sponsors
Intensive Care
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Age >70 years ; Admitted to the ICU and institution of invasive mechanical ventilation Intravenously administration of midazolam; Expected midazolam administration for at least 12 hours;
Exclusion criteria
Exclusion criteria: Use of CYP3A4 inhibitors or inductors at the start of the study; o Strong to very strong CYP3A4 inhibitors: boceprevir, clarithromycin, erythromycin, grapefruit juice, indinavir, itraconazole, ketoconazole, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin and voriconazole. o Strong to very strong CYP3A4 inductors: carbamazepine, dabrafenib, rifampicin and Saint John`s-wort. Patients participating in another study; Prescription of other sedatives (except fentanyl); Patients suffering from cerebral condition, that may influence RASS scores.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main study parameters/endpoints: The pharmacokinetic profile of midazolam in elderly patients on the ICU. | — |
Secondary
| Measure | Time frame |
|---|---|
| - To determine the elimination half-life of midazolam in elderly patients on the ICU; - To determine whether accumulation of midazolam occurs in elderly patients on the ICU; - To determine the metabolic capacity of the liver by the ratio midazolam/1-hydroxy midazolam in elderly patients on the ICU. - To gain basic insight in the effect of factors, that are present on the ICU such as: ldecreased kidney function, inflammatory state, cardiac function and body mass on the pharmacokinetic profile of midazolam. | — |
Countries
Netherlands
Outcome results
None listed